References
- Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, Dickinson RG. (2000). Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. Eur J Clin Pharmacol 56:715–721.
- Casida JE, Quistad GB. (2004). Organophosphate toxicology: safety aspects of nonacetylcholinesterase secondary targets. Chem Res Toxicol 17:983–998.
- De Turck BJ, Diltoer MW, Cornelis PJ, Maes V, Spapen HD, Camu F, Huyghens LP. (1998). Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother 42:563–564.
- Drawz SM, Bonomo RA. (2010). Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160–201.
- Kahan JS, Kahan FM, Goegelman R, Currie SA, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, Hernandez S, Woodruff HB, Birnbaum J. (1979). Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot 32:1–12.
- Lu WP, Kincaid E, Sun Y, Bauer MD. (2001). Kinetics of beta-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae. Involvement of acylation and deacylation in beta-lactam resistance. J Biol Chem 276:31494–31501.
- Masuo Y, Ito K, Yamamoto T, Hisaka A, Honma M, Suzuki H. (2010). Characterization of inhibitory effect of carbapenem antibiotics on the deconjugation of valproic acid glucuronide. Drug Metab Dispos 38:1828–1835.
- Mitta M, Ohnogi H, Mizutani S, Sakiyama F, Kato I, Tsunasawa S. (1996). The nucleotide sequence of human acylamino acid-releasing enzyme. DNA Res 3:31–35.
- Nagai K, Shimizu T, Togo A, Takeya M, Yokomizo Y, Sakata Y, Matsuishi T, Kato H. (1997). Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother 39:295–296.
- Nakajima Y, Mizobuchi M, Nakamura M, Takagi H, Inagaki H, Kominami G, Koike M, Yamaguchi T. (2004). Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 32:1383–1391.
- Nakamura Y, Nakahira K, Mizutani T. (2008). Decreased valproate level caused by VPA-glucuronidase inhibition by carbapenem antibiotics. Drug Metab Lett 2:280–285.
- Roy AB, Hewlins MJ. (1994). On the reactions of the carbapenem, meropenem, in the soluble fraction of rat kidney. Xenobiotica 24:185–198.
- Sumita Y, Fukasawa M, Mitsuhashi S, Inoue M. (1995). Binding affinities of beta-lactam antibodies for penicillin-binding protein 2’ in methicillin-resistant staphylococcus aureus. J Antimicrob Chemother 35:473–481.
- Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, Miura S, Okazaki O. (2010). Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos 38:1538–1544.
- Yamamura N, Imura K, Naganuma H, Nishimura K. (1999). Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos 27:724–730.
- Yamashita N, Kawashima K, Nomura K, H. T, T. W, and T. N. (1994). Pharmacokinetics of [14C]biapenem in rats. Chemotherapy (Tokyo). 42 Suppl 4:251–267.
- Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. (2007). Comparative review of the carbapenems. Drugs 67:1027–1052.